Objective: To evaluate recent trends in the cost of percutaneous transluminal coronary angioplasty (PTCA), particularly the impact of newer technology and changing patient profile.
Study design: Retrospective study with a 6-month follow up.
Patients and methods: We compared the data on two groups of 100 consecutive patients admitted for elective PTCA at Yale-New Haven Hospital in 1995 and 1996. Hospital records, cineangiograms, and hospital cost accounting system were reviewed, and 6-month clinical outcomes were obtained from telephone interviews and medical chart review.
Results: Demographic and clinical characteristics did not differ between the 1995 and 1996 groups of patients, nor was a difference detected in in-hospital and 6-month clinical outcomes between 1995 and 1996. Angiographic features of treated lesions were different between the two groups, with a significantly higher frequency of type C and totally occluded lesions in 1996 (p = 0.002 and p = 0.04, respectively). The total hospital costs were higher in 1996 compared with 1995 ($11,799 +/- $6189 vs $10,087 +/- $5608; p = 0.04). This difference persisted after adjustment for changes in patient population. The major factor responsible for escalating costs was a 45% increase in catheterization laboratory costs ($8575 +/- $4524 in 1996 vs $5916 +/- $3030 in 1995; P < 0.0001). In contrast, the noncatheterization costs decreased substantially during this period, largely as a result of an approximately 33% decrease in length of stay (3.75 +/- 2.66 days in 1995 vs 2.57 +/- 1.99 days in 1996; P = 0.0005). In a multiple linear regression model, the most important determinants of cost were lesion characteristics, stent use, and radiographic contrast volume.
Conclusions: Despite cost reduction efforts, the costs of PTCA are rising because of increased consumption of resources in the catheterization laboratory.